The Chemours Company

NYSE:CC 주식 리포트

시가총액: US$4.1b

Chemours 과거 순이익 실적

과거 기준 점검 0/6

Chemours 의 수입은 연평균 -49.4%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 0.6%의 비율로 증가했습니다. 매출은 연평균 0.3%의 비율로 감소해 왔습니다.

핵심 정보

-49.39%

순이익 성장률

-48.91%

주당순이익(EPS) 성장률

Chemicals 산업 성장률12.93%
매출 성장률-0.28%
자기자본이익률-153.78%
순이익률-6.65%
다음 순이익 업데이트06 May 2026

최근 과거 실적 업데이트

Recent updates

Chemours: Thesis Materialization In 2026 (Rating Downgrade)

May 04

CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside

Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).

CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside

Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).

CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership

Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).

CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook

Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.

CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside

Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.

CC: PFAS Class Action Risk Will Limit Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.

The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth

CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook

Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).

CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns

Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.

CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks

Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).

CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks

Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).

CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher

Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).

Low GWP Refrigerants And Advanced Materials Will Drive Future Success

The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.

The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%

Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?

The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Chemours (NYSE:CC) Has No Shortage Of Debt

Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt

We Like The Quality Of Chemours' (NYSE:CC) Earnings

May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings

Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?

What Is The Chemours Company's (NYSE:CC) Share Price Doing?

Mar 19
What Is The Chemours Company's (NYSE:CC) Share Price Doing?

It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

Mar 04
It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks

Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt

Jan 24
Chemours (NYSE:CC) Seems To Be Using A Lot Of Debt

Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?

Jan 08
Are Investors Undervaluing The Chemours Company (NYSE:CC) By 50%?

매출 및 비용 세부 내역

Chemours가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NYSE:CC 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
31 Dec 255,808-386504108
30 Sep 255,837-320577107
30 Jun 255,850-412611111
31 Mar 255,78828587108
31 Dec 245,78269618109
30 Sep 245,83563557109
30 Jun 245,814106505107
31 Mar 245,904-329538110
31 Dec 236,078-2531,286108
30 Sep 236,004-317567112
30 Jun 236,294-87624117
31 Mar 236,566489689114
31 Dec 226,831578705118
30 Sep 227,031908688117
30 Jun 226,933881670111
31 Mar 226,673746560113
31 Dec 216,345608583107
30 Sep 216,108394582104
30 Jun 215,662256572100
31 Mar 215,10021553993
31 Dec 204,96921952693
30 Sep 204,984-11746386
30 Jun 205,140-11747283
31 Mar 205,455-4650882
31 Dec 195,526-5253680
30 Sep 195,63740760082
30 Jun 195,87660661083
31 Mar 196,28479264784
31 Dec 186,63899563082
30 Sep 186,7491,08160380
30 Jun 186,7051,01359780
31 Mar 186,47689357882
31 Dec 176,18374659281
30 Sep 175,93028858282
30 Jun 175,74428560581
31 Mar 175,54010661676
31 Dec 165,400759181
30 Sep 165,43815160589
30 Jun 165,526-8261587
31 Mar 165,651-8259897
31 Dec 155,717-9063297
30 Sep 155,90675634101
30 Jun 156,052211653116

양질의 수익: CC 은(는) 현재 수익성이 없습니다.

이익 마진 증가: CC는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: CC은 수익성이 없으며 지난 5년 동안 손실이 연평균 49.4% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 CC의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: CC은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(0.1%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: CC는 현재 수익성이 없으므로 자본 수익률이 음수(-153.78%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/05 19:21
종가2026/05/05 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

The Chemours Company는 19명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullAlembic Global Advisors
David ColemanArgus Research Company
Michael LeitheadBarclays